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NeuroprotectionRopinirole, an agonist of the post-synaptic dopamine D2-receptor, exerts neuroprotective activity. The
mechanism is still under discussion. Assuming that this neuroprotection might be associated with inhibition
of the apoptotic cascade underlying cell death, we examined a possible effect of ropinirole on the
permeability transition pore (mtPTP) in the mitochondrial inner membrane. Using isolated rat liver
mitochondria, the effect of ropinirole was studied on Ca2+-triggered large amplitude swelling, membrane
depolarization and cytochrome c release. In addition, the effect of ropinirole on oxidation of added,
membrane-impermeable NADH was investigated. The results revealed doubtlessly, that ropinirole can
inhibit permeability transition. In patch-clamp experiments on mitoplasts, we show directly that ropinirole
interacts with the mtPTP. Thus, ropinirole reversibly inhibits the opening of mtPTP with an IC50 of 3.4 µM and
a Hill coefﬁcient of 1.3. In both systems (i.e. energized mitochondria and mitoplasts) the inhibitory effect on
permeability transition was attenuated by increasing concentrations of inorganic phosphate. In addition, we
showed with antimycin A-treated mitochondria that ropinirole failed to suppress respiratory chain-linked
reactive oxygen species release. In conclusion, our data suggest that the neuroprotective activity of ropinirole
is due to the blockade of the Ca2+-triggered permeability transition.e c; FCCP, carbonyl cyanide 4-
centration causing 50% inhibi-
; PD, Parkinson's disease; RBM,
S, reactive oxygen species; Pi,
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The characteristic feature of Parkinson's disease (PD), a neurode-
generative disorder, is the progressive loss of dopaminergic neurons
of the substantia nigra, resulting in a deﬁciency of dopamine in the
corpus striatum. Ropinirole, a non-ergoline dopamine-D2-agonist
which is strongly active at D2/D3 receptor sites, but has negligible
activity at D1 receptor sites [1], is an effective drug for the treatment of
PD symptoms [2]. In addition, ropinirole binds to the dopamine type 2
autoreceptors, thereby reducing dopamine release. This activity of
ropinirole is important because oxidative dopamine inactivation by
the monoaminooxidase is a source of reactive oxygen species (ROS),
which are likely to damage oxidatively nigrostriatal tissue [3].
Interestingly, it has been discussed that ropinirole could scavengeROS directly, as well as, indirectly via activation of enzymes of the
antioxidative cellular defense system, such as the glutathione
peroxidase, the catalase, and the superoxide dismutase [4].
Recent attention has focused on the possible role of dopamine
agonists in neuroprotection, probably by inhibition of the apoptotic
cell death. Mitochondria are playing a critical role in apoptotic cell
death, by releasing several apoptotic factors (such as cytochrome c,
Cyt c). It has been proposed that opening of the mitochondrial
permeability transition pore (mtPTP) is somehow related to the
release of these apoptotic factors [5]. The underlying permeabilization
of the inner mitochondrial membrane to non-permeable solutes
abolished the electrochemical proton gradient, thereby impairing
energy-dependent mitochondrial functions, e.g. ATP generation or
calcium sequestration (for review see [6]). Various effectors,
mostly Ca2+, inorganic phosphate (Pi), protonophoric uncouplers or
oxidants of critical SH-groups initiate opening of the mtPTP [7–9]. The
molecular identity of the mtPTP is still unknown [10–12]. It appears
to operate as a Ca2+-, Pi-, voltage-, pH-, and redox-gated channel
[12–15].
In two previous studies it was shown that pramipexole, also a
dopamine-D2-agonist, can inhibit opening of the mtPTP [16,17]. This
is a surprising observation suggesting that D2-receptor agonists
(chemical structures of pramipexole and ropinirole are given in Fig. 1)
could desensitize mtPTP against opening. To further substantiate this
hypothesis, we examined the effect of ropinirole on the mtPTP by
Fig. 1. Chemical structures of pramipexole and ropinirole.
1246 S. Parvez et al. / Biochimica et Biophysica Acta 1797 (2010) 1245–1250using both, isolated mitochondria and mitoplasts. To compare patch-
clamp-studies at a single mitochondrium, with studies done with
mitochondrial incubations (measurement of swelling, membrane
polarisation, etc.), we used mostly rat liver mitochondria for practical
reasons. We report here that a dose-dependent block of the mtPTP by
ropinirole has been found, an activity which might contribute to its
clinically observed neuroprotective effect.
2. Materials and methods
2.1. Preparation of mitochondria
Livermitochondria were prepared from adultWistar rats (RLM) by
differential centrifugation. Brieﬂy, the liver was homogenized in an
ice-cold isolation buffer containing 0.25 M sucrose, 1 mM EDTA
adjusted by Tris to pH 7.4, and centrifuged at 800 g for 5 min. The
supernatant was centrifuged at 5100 g for 4 min. Thereafter, the
obtained pellet was resuspended again in a 0.25 M sucrose medium
adjusted by Tris to pH 7.4, and centrifuged at 12,300 g for 2 min.
Finally, the pellet was resuspended in a 0.25 M sucrose medium
adjusted by Tris to pH 7.4, centrifuged at 12,300 g for 10 min, and
resuspended in a buffer containing 0.25 M sucrose, 0.5 mM EDTA
adjusted by Tris to pH 7.4. The protein concentration of the stock
suspension was 20–35 mg/mL as determined using the biuret
method. Mitochondria from rat brain (RBM) were prepared as
described in [18].
2.2. Monitoring of the Ca2+-triggered permeability transition
2.2.1. Swelling measurements
Aliquots of the mitochondrial stock suspension (RLM, 1 mg of
protein/mL) were added to an incubation medium containing
125 mM KCl, 20 mM Trizma base, 1 mM MgCl2, 1 µM EGTA, 5 mM
glutamate, and 5 mM malate (pH 7.2). Permeability transition was
induced by addition of CaCl2 and monitored by measuring the
decrease of light scattering due to the large amplitude swelling of
mitochondria at 540 nm using a Varian Cary 3 spectrophotometer at
30 °C. Swelling was recorded during a period of 10 min and is
expressed as a percentage of initial absorbance.
2.2.2. Monitoring of the mitochondrial membrane potential (Δψm)
Depolarization of the inner mitochondrial membrane was moni-
tored with the membrane-permeable cation safranine O using the
Perkin-Elmer Luminescence Spectrophotometer LS 50B (excitation
495 nm, emission 586 nm) as ﬁrst described in [19]. Aliquots of the
mitochondrial stock suspension (RLM or RBM, 1 mg of protein/mL)
were suspended in incubation medium (see Section 2.2.1). Further
additions were 5 µM safranine O and different concentrations of Pi
(0.1, 2.0 mM; 0 mM Pi as a control).
2.3. Measurement of H2O2 release
Generation of O2•− was measured as the release of H2O2 from
mitochondria using the Amplex Red/horseradish peroxidase (HRP)
system. The non-ﬂuorescent Amplex Red becomes oxidized by H2O2to the ﬂuorescent resoruﬁn. Brieﬂy, mitochondria (0.2 mg of
mitochondrial protein/mL) were incubated at 25 °C in incubation
medium (see Section 2.2.1) supplemented with 5 µM Amplex Red,
2 U/mLHRP and, in addition, 2 U/mL Cu,Zn-superoxide dismutase, for
quantitative conversion of O2•− into H2O2. The increase in the
ﬂuorescence was monitored using a Perkin-Elmer LS-50B ﬂuores-
cence spectrometer (excitation at 560 nm, emission at 590 nm).
Fluorescence signals were calibrated by additions of known quantities
of H2O2.
2.4. Respiration measurements
The oxygen consumption of RLM was measured at 30 °C using the
high-resolution Oroboros oxygraph (Anton Paar, Graz). The measure-
ments were performed in incubation medium, supplemented either
with 0.1 mM or 10 mM Pi. For the measurement of the Ca2+-
dependent respiration, free calcium concentrations were calculated
by means of the BAD3-program which is based on the equations
reported in [20].
2.5. Cytochrome c release
Mitochondria (1 mg of protein) were incubated in 1 mL of
incubation medium, supplemented with 2 mM Pi. Effectors were
applied for 5 min at 30 °C in the same way as given in the legend of
Fig. 3. The suspension was then centrifuged at 12,300×g for 3 min. An
aliquot of the supernatant (0.5 mL) was carefully removed, and the
protein therein precipitated with acetone-deoxycholate. The precip-
itated protein or mitochondrial pellet was dissolved in 0.5 mL buffer
composed of 66 mM Tris, 10% glycerol, 2% SDS, 0.003% bromphenol
blue and 5 mg/mL of dithiothreitol, pH 6.8. For immunoblots, 50 µL
aliquots of dissolved supernatant protein or 50 µL aliquots of
dissolved pellet protein (1:10 diluted) were run on 15% polyacryl-
amide gels. Thereafter, the separated proteins were electrotransferred
to PVDF membranes (transfer buffer: 25 mM Tris–HCl pH 8.3; 20%
methanol) that were rinsed with transfer buffer and blocked
overnight in blocking buffer (137 mM NaCl, 10 mM Tris, pH 7.3)
supplemented with 5% milk powder. Cyt c was immunostained with
mouse anti-cytochrome c antibody [7H8] (1:500) from PharMingen
(BD Biosciences, Erembodgem, Belgium) plus secondary anti-mouse
Ig bound to horseradish peroxidase (1:5000) from Dianova (Ham-
burg, Germany). Peroxidase activity was detected using the enhanced
chemiluminescence detection kit (Amersham, Ismaning, Germany)
and X-ray ﬁlm.
2.6. Patch-clamp measurements
Single-channel currents were recorded from mitoplasts using the
patch-clamp technique [17]. Mitochondria were subjected to a
hypotonic treatment (1 min with a solution composed of 5 mM K-
HEPES and 1 mM CaCl2, pH 7.2) in order to break the outer membrane
(OM). Thereafter, isotonicity was restored by adding a solution
composed of 750 mM KCl, 80 mM K-HEPES, and 1 mM CaCl2 (pH 7.2).
This procedure resulted in swollen mitochondria (mitoplasts, 5–
20 µm diameters), which had lost their OM. Electrodes were made
from borosilicate-glass (Harvard, Edenbridge, UK) with resistances of
10–20 MΩ. Current was recorded by means of an EPC-7 patch-clamp
ampliﬁer (HEKA electronics, Lambrecht, Germany). Free-ﬂoating
mitoplasts were approached by means of an electrically driven
micromanipulator and attached to the tip of the pipette by gentle
suction. Standard pipette and bath solutions consisted of 150 mMKCl,
20 mM K-HEPES, and 0.1 mM CaCl2 (pH 7.2). Test solutions were
added through the glass capillaries of a peristaltic-pump driven ﬂow
system at room temperature. Currents were low-pass ﬁltered at a
frequency of 0.5 kHz and sampled at 2.5 kHz. Analysis was done using
Fig. 3. Phosphate attenuates ropinirole-induced inhibition of the permeability
transition. RLM (1 mg of protein/mL) were added to incubation buffer supplemented
with 10 µM safranine O. In control incubations (traces A, C, E) mitochondria were not
pretreated with ropinirole. In traces B, D, F, mitochondria were pretreated with 100 µM
ropinirole. To initiate the opening of mtPTP, Ca2+ was added as in Fig. 2. Pi con-
centrations were added as indicated. Increase in safranine ﬂuorescence indicates
depolarization of the inner mitochondrial membrane. Complete depolarization was
obtained with FCCP (50 nM).
1247S. Parvez et al. / Biochimica et Biophysica Acta 1797 (2010) 1245–1250the Pclamp 9.2 software (Axon instruments, Foster City, CA). The open
probability (Po) was determined as described previously [17,21].
2.7. Materials
ADP, CsA, horseradish peroxidase, Cu,Zn-superoxide dismutase,
cytochrome c, carbonyl cyanide 4-(triﬂuoromethoxy)phenylhydra-
zone, antimycin A, NADH, safranine O, and CaCl2 were purchased from
Sigma (Deisenhofen, Germany). Amplex Red was from Invitrogen
(Karlsruhe, Germany), ropinirole (4-[2-(dipropylamino)ethyl]-1,3-
dihydro-2H-indol-2-one monohydrochloride) was obtained from
GlaxoSmithKline (Brentford, Middlesex, UK).
3. Results
3.1. Effect of ropinirole on Ca2+ triggered permeability transition
The effects of various concentrations ropinirole on the opening of
the mtPTP by Ca2+ is shown with energized rat liver mitochondria in
Fig. 2. Large amplitude swelling was obtained with 50 nmol Ca2+/mg
of protein. This swelling was completely prevented in the presence of
1 µM of the mtPTP-inhibitor CsA. Ropinirole inhibited the Ca2+-
triggered permeability transition completely and dose-dependently
with a half-maximal inhibitor concentration (IC50) of 50 µM.
Furthermore, the Ca2+-triggered permeability transition was moni-
tored by the depolarization of the inner mitochondrial membrane
using the cationic Δψm-probe safranine O. The increase of the
safranine ﬂuorescence after addition of Ca2+ (50 nmol/mg of protein)
indicates onset of permeability transition (Fig. 3A, C, E). The
protonophore FCCP (50 nM) was used to induce complete depolar-
ization. In order to examine the effect of ropinirole on the Ca2+-
triggered depolarization, mitochondria were preincubated with
50 µM ropinirole (Fig. 3B, D, F). Ropinirole partially inhibited the
depolarization in the absence as well as in the presence of low Pi
concentrations (≤µL 0.1 mM) (Fig. 3B, D). However, ropinirole failed
to prevent the depolarization at 2 mM Pi (Fig. 3F). The Ca2+-triggered
permeability transition was further substantiated as the release of Cyt
c from the intermembrane space. Similar to CsA, ropinirole prevented
the Ca2+-induced release of Cyt c (not shown).
3.2. Effect of ropinirole on Ca2+-induced oxidation of external NADH
The intact inner mitochondrial membrane is impermeable to
NADH. Therefore, rat liver mitochondria are unable to use externalFig. 2. Ropinirole inhibits Ca2+-triggered mitochondrial large amplitude swelling.
Mitochondria (RLM; 1 mg of protein/mL) were energized with glutamate plus malate
(5 mM/5 mM). Opening of the mtPTP was initiated by addition of CaCl2 (ﬁnal
concentration 50 µM, corresponding to 50 nmol Ca2+/mg mitochondrial protein).
Large amplitude swelling after addition of Ca2+ indicates opening of the mtPTP
(permeability transition). CsA (5 µM) completely suppressed Ca2+ swelling. RLM were
pretreated (4 min) with the indicated concentrations of ropinirole. Representative data
from three independent experiments are shown.NADH as fuel for establishing the electrochemical proton gradient.
However, after opening of the mtPTP by Ca2+, external NADH can
enter thematrix compartment where it is oxidized by complex I of the
respiratory chain. To examine if ropinirole can protect themtPTP from
opening, we measured the mitochondrial respiration with external
NADH after inducing opening of the mtPTP by Ca2+ [22].
A typical experiment demonstrating the changes in respiration is
shown in Fig. 4 (panels A−C). RLM exhibited slow basal respiration in
the absence of Ca2+. Addition of Ca2+ (65 µM) induced a transient
increase of oxygen uptake due to the electrophoretic Ca2+-uptake
into the mitochondrial matrix compartment. This addition of Ca2+
initiated opening of the mtPTP, which slightly enhanced basal
respiration due to uncoupling of the mitochondria (Fig. 4A). Fully
uncoupled respiration was not seen since matrix-NAD, as a coenzyme
of complex I, became strongly diluted under this condition. However,
when NADH (1 mM) was subsequently added the oxygen uptake was
enhanced dramatically indicating access of the added NADH to
complex I. In contrast, no change of the oxygen uptake occurred
after NADH addition, when opening of the mtPTP was blocked by CsA
(Fig. 4B). A similar result was obtained with ropinirole (≥µL 100 µM,
Fig. 4C).
3.3. Brain mitochondria and possible side effects of ropinirole
To account for the possible signiﬁcance of the ropinirole-linked
inhibition of the permeability transition in neuroprotection, we
applied ropinirole to energized rat brain mitochondria (RBM). Firstly,
the effect of ropinirole (100 µM) was studied by monitoring FCCP-
triggered opening of the mtPTP, as shown in Fig. 5. To sensitize RBM
for undergoing FCCP-triggered permeability transition, mitochondria
were ﬁrst loaded with an incremental amount of Ca2+ (Fig. 5B).
Fig. 4. Ropinirole prevents oxidation of external NADH by Ca2+-treated mitochondria.
Changes in medium-oxygen concentration and that of its ﬁrst-derivative (rate of
respiration) of the control incubation are shown. RLM (0.33 mg of protein/mL)
were added to substrate-free incubation medium. Glutamate plus malate (Glu/Mal;
5 mM/5 mM), Ca2+ (50 µM), and NADH (1 mM) were added as indicated. A: Opening
of the mtPTP by Ca2+ enables mitochondria to oxidize the NADH added, resulting in an
increased rate of respiration. B: In the presence of CsA (2 µM) oxidation of added NADH
is blocked. C: The rate of respiration of RLM pretreated with ropinirole (1 mM) is
inhibited, as well. The data shown are representative of three experiments.
Fig. 5. Effect of ropinirole on respiration, permeability transition, and ROS using brain
mitochondria. A: The effects of four increasing ropinirole concentrations (plus control)
on the resting (open triangles) and ADP-induced respiration (State 3 respiration, ﬁlled
triangles) of mitochondria from one rat brain are shown. State-3 respiration (41 nmol
O2/min/mg of protein) was stimulated by 2 mM of ADP. B: The effect of ropinirole on
FCCP-triggered permeability transition is shown. RBM (1 mg/mL) were preloaded with
Ca2+ (50 nmol/mg protein), the ﬁnal concentration of FCCP was 0.05 µM. C: The effect
of ropinirole (0.1 or 1 mM) on the release of ROS by antimycin A-inhibited
mitochondria is shown. Final concentration of antimycin A was 5 µM. All experiments
were done in incubation medium supplemented with 0.1 mM Pi.
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can be seen, ropinirole clearly inhibited the permeability transition-
linked depolarization.
Furthermore, we examined a possible effect of ropinirole on the
respiration of resting and of phosphorylating mitochondria. It was
found that ropinirole affects respiration only slightly, even when it
was applied up to 2 mM (Fig. 5A). Consequently, ropinirole
does not act as an uncoupler or as an inhibitor of the oxidative
phosphorylation.
Finally, we examined a possible antioxidative activity of ropinirole
on the respiratory chain-generated ROS release by the mitochondria.
For this purpose, the mitochondrial ROS production was stimulatedby impairing the respiratory chain with the complex III-inhibitor
antimycin A. ROS production was estimated by monitoring the H2O2
release using the Amplex Red/HRP system. Panel C of Fig. 5 shows
clearly that ropinirole applied within the concentration range of 0.1 to
1 mMdoes not diminish H2O2 release, thereby excluding a direct H2O2
scavenging activity of ropinirole.3.4. Effect of ropinirole on mtPTP in mitoplasts
In order to show the blocking effect of ropinirole directly upon the
mtPTP, patch-clamp techniques were applied for measuring single-
channel currents in liver mitoplasts. The recordings from patches with
sufﬁcient seal resistance showed a Ca2+-induced channel conduc-
tance of more than 1 nS and a large variety of subconductances, which
are typical features of the mtPTP. A complete block by ropinirole was
Fig. 7. Concentration–response curve for the normalised open probability (Po) under
the inﬂuence of ropinirole at Eh=+20 mV. Po was estimated by all point analysis of
single-channel data in 3 to 5 1-min segments before ropinirole application and in 3 to 5
1-min segments after addition of ropinirole. Mean Po was calculated from up to 4
experiments at each concentration. Continuous curve was calculated by means of the
Hill equation. Data are presented as the mean±SE.
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concentration, the effect was reversible upon washout in the control
solution (Fig. 6, trace 4). The channel events could be dose-
dependently and reversibly blocked by the mtPTP-inhibitor CsA
(Fig. 6, traces 5 and 6), as was described previously for other inhibitors
[13,16,21]. The analysis of the patch-clamp experiments showed that
ropinirole inhibited the open probability (Po) of the mtPTP at
concentrations ranging from 30 nM to 10 µM. The best ﬁt of the
concentration–response curve was obtained with an IC50 of 3.4 µM
and a Hill coefﬁcient of 1.3 (Fig. 7).
As the IC50 is approximately an order of magnitude lower than in
the swelling experiments we hypothesized that the missing Pi could
explain this observation. Therefore, additional experiments were
performed to investigate the role of increased Pi concentrations for
the blocking effect of ropinirole. 10 µM ropinirole in combinationwith
10 mM Pi did not exhibit a similar blocking effect as 10 µM ropiniroleFig. 6. Representative current traces of mtPTP conductivity before, during, and after
application of ropinirole or CsA. Baseline PTP activity (control, 1st trace) was blocked by
5 µM ropinirole (2nd and 3 rd trace, at 58 and 171 s, respectively, after switching to
ropinirole). Reversibility (4th trace, after switching to control). A different experiment
shows vanishing single-channel activity 20 s (5th trace) and 27.5 s (6th trace) after
1 µM CsA as a control for the identity of themtPTP. Dashed lines and arrows indicate the
fully closed state. Holding potential (Eh): +20 mV.alone, and a similar trend was observed in the case of 1 µM CsA alone
and in combination with 10 mM Pi, where high Pi concentration
attenuated the blocking effect of CsA (Fig. 8).
4. Discussion
Mitochondria exert a key function in apoptotic cell death (for
review, [23]). This view has stimulated the search for drugs, which are
able to protect mitochondria against permeability transition. In this
study, we examined a possible inhibitory activity of ropinirole, a non-
ergoline dopamine-D2-receptor agonist, on the opening of the mtPTP.
The effect of ropinirole on mtPTP opening was demonstrated with
liver mitochondria by mitochondrial swelling, membrane depolariza-
tion, Cyt c release and the oxidation of external NADH after treatment
with Ca2+. In our second approach, we examined the effect of
ropinirole on the mtPTP-based conductance using mitoplasts. Despite
mitoplasts being energetically impaired they offer the advantage to
reveal a possible interaction of ropinirole with the mtPTP more
directly. We have shown that ropinirole is able to block the Ca2+-
triggered opening of mtPTP in isolated, energized liver mitochondria
(Figs. 2 and 3). This ﬁnding was further substantiated by demon-
strating an inhibitory activity of ropinirole on mtPTP mediated
membrane-conductivity in mitoplasts (Figs. 6–8). Importantly, ropi-
nirole lowered the open probability (Po) of the mtPTP at pharmaco-
logical low concentrations, ranging from 30 nM to 10 µM. Keeping in
mind, that ropinirole is a doubled-charged cation at physiological pH
[24], there is reason to assume that it can bind to negatively-chargedFig. 8. Phosphate attenuates the inhibitory activity of ropinirole on mtPTP-based
conductivity of mitoplasts. Mean Po-values (±SE) of experiments with 1 µM ropinirole
(0.83, n=3) or 10 µM ropinirole (0.15, n=4) alone or with ropinirole (10 µM) plus Pi
(10 mM) in ﬂow system only (0.57, n=4), as compared with mean Po before adding
test substances. Reduction was signiﬁcant in these three measurements on the 5%, 1%
and on the 5% level, respectively. Experiments were also performed with CsA (1 µM)
alone (0.09, n=3) or with CsA (1 µM) plus Pi (10 mM) in ﬂow system only (0.40,
n=3) as a positive control. Reduction was signiﬁcant on the 1% and on the 5% level,
respectively.
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lipophilicity of ropinirole (log partition coefﬁcient (octanol/phos-
phate buffer)=3.31) suggests that it can permeate biological
membranes easily [24]. Taken together, from both, lipophilicity and
cationic nature of ropinirole, it is likely that ropinirole becomes
enriched in the mitochondrial matrix compartment driven by Δψm.
Thus, ropinirole could bind to the cytosolic-side and/or to the matrix-
side of the mtPTP complex.
The inhibitory activity of ropinirole on the mtPTP opening is
concentration-dependently antagonized by Pi (Fig. 3). When mito-
chondria were suspended in 1 mM Pi-containing medium, the
inhibitory activity of ropinirole was signiﬁcantly reduced. With
mitoplasts, a similar Pi-sensitivity of the inhibitory effect of ropinirole
on the Ca2+-induced mtPTP opening was found. Attenuation of the
ropinirole-linked inhibition of the opening of the mPTP by Pi ﬁts well
with the fact, that Pi is generally referred to act as a PTP inducer [25].
In addition, a direct interaction of the negatively-charged Pi with the
mtPTP-bound ropinirole or with the free ropinirole itself could
contribute to this attenuating effect of Pi. In the ﬁrst case, it is
likely that Pi removed ropinirole from the mtPTP, whereas in the
second case Pi decreased the effective ropinirole concentration in the
medium.
Moreover, it became evident recently that the relationship
between Pi and mtPTP opening is much more complex than
previously thought (see for a recent review [26]). Due to these results
Pi is necessary for the CsA inhibition of themtPTP [14]. In this case, the
‘co-inhibitory activity’ of Pi might be attributed to a distinct
interaction of Pi with the mtPTP itself or with the mtPTP-inhibitor
complex. In this context it is important that addition of Pi to
mitochondria suspended in Pi-free medium decreases the matrix-
pH (Pi is co-transported with H+ or in exchange to OH−), an
observation paralled by an increase in Δψm [27]. This decrease of
matrix-pH is likely to change the protonation of critical histidyl
residues of the mtPTP thus preventing the inhibitor complex from
binding to the mtPTP [28].
It has been discussed also that neuroprotection by ropinerole could
be partly attributed to direct ROS scavenging and/or an activation of
the cellular enzymatic antioxidative defense system [4]. Our results do
not support such activity of ropinirole (Fig. 5C).
Finally, a crucial issue is: could ropinirole inhibit opening of the
mtPTP in human brain tissue at concentrations used therapeutically?
There are several arguments for an inhibitory effect of ropinirole
on the mtPTP under these conditions. First, a blockade of the Ca2+-
triggered permeability transition is also found in experiments with
mitochondria isolated from rat brain (Fig. 5B). Secondly, as mentioned
above, ropinirole is a highly lipophilic compound, suggesting that it
permeates biological membrane easily. Thirdly, when patients are
treated with so-called “tid-dosing” (4 mg), the serum concentration
of ropinirole could be increased up to 100 nM [29]. Moreover, due to
the existing membrane potentials at the plasma membrane (about
−60 mV) and the inner mitochondrial membrane (about−150 mV),
a 102- and 107-fold accumulation of the double-positive-charged
ropinirole is calculated for the cytosolic compartment and the matrix
compartment, respectively. However, the concentration of free
ropinirole in both compartments should be much lower, since it is
likely that it binds to anionic binding-sites of membrane phospholi-
pids and proteins. In conclusion, this study suggests that there is good
reason to assume that ropinirole is active as an inhibitor of the mtPTP
under in vivo conditions.
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